Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 42, Issue 10 (Oct 2004)


Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence

Marco Di Tola
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Luigi Sabbatella
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Maria Cristina Anania
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Angelo Viscido
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Renzo Caprilli
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Roberta Pica
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Paolo Paoluzi
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
/ Antonio Picarelli
  • Department of Clinical Sciences, University “La Sapienza”, Rome, Italy
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2004.225


Anti-tissue transglutaminase, previously held to be identical to anti-endomysial antibodies in celiac sprue, has been reported in inflammatory bowel disease patients. To investigate these data further, we evaluated serum and intestinal anti-tissue transglutaminase in inflammatory bowel disease patients, with respect to the Crohn’s disease activity index and the integrated disease activity index. Study population comprised: 49 patients with Crohn’s disease and 29 patients with ulcerative colitis; 45 patients with celiac sprue and 85 autoimmune patients as disease controls; and 58 volunteers as healthy controls. Immunoglobulin A (IgA) anti-recombinant human tissue transglutaminase and anti-endomysial antibody detection in sera and fecal supernatants were performed. Adsorption of positive sera with recombinant human tissue transglutaminase were also performed. Marked increased anti-tissue transglutaminase concentrations were found in celiac sprue, while low-positive values were also found in Crohn’s disease and ulcerative colitis. Anti-endomysial antibodies were detectable only in celiac sprue. Antigen adsorption resulted in a significant reduction of the anti-tissue transglutaminase either in celiac sprue or inflammatory bowel disease sera. A significant correlation between anti-tissue transglutaminase and Crohn’s disease activity index or integrated disease activity index scores was found. Anti-tissue transglutaminase was also detectable in fecal supernatants from inflammatory bowel disease patients. Data highlight that both circulating and intestinal anti-tissue transglutaminases are detectable in inflammatory bowel disease, and that they are related to disease activity. These features underline that, in addition to anti-tissue transglutaminase, an anti-endomysial antibody test is necessary in the diagnostic work-up of celiac sprue, especially in patients with known inflammatory bowel disease.

Keywords: anti-endomysial; celiac sprue; Crohn’s disease; transglutaminase; ulcerative colitis


  • 1

    Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. Fed Am Soc Exp Biol J 1991; 5:3071–7.Google Scholar

  • 2

    Piacentini M. Tissue transglutaminase: a candidate effector element of physiological cell death. Curr Top Microbiol Immunol 1995; 200:163–75.Google Scholar

  • 3

    Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 7:797–801.CrossrefGoogle Scholar

  • 4

    Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001; 120:636–51.CrossrefGoogle Scholar

  • 5

    Sulkanen S, Halttunen T, Laurila K, Kolho KL, Korponay-Szabo IR, Sarnesto A, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998; 115:1322–8.CrossrefGoogle Scholar

  • 6

    Koop I, Ilchmann R, Izzi L, Adragna A, Koop H, Barthelmes H. Detection of autoantibodies against tissue transglutaminase in patients with celiac disease and dermatitis herpetiformis. Am J Gastroenterol 2000; 95:2009–14.CrossrefGoogle Scholar

  • 7

    Farrace MG, Picarelli A, Di Tola M, Sabbatella L, Marchione OP, Ippolito G, et al. Presence of anti-“tissue” transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event? Cell Death Diff 2001; 8:767–70.CrossrefGoogle Scholar

  • 8

    Carroccio A, Vitale G, Di Prima L, Chifari N, Napoli S, La Russa C, et al. Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clin Chem 2002; 48:1546–50.Google Scholar

  • 9

    Picarelli A, Sabbatella L, Di Tola M, Di Cello T, Vetrano S, Anania MC. Antiendomysial antibody detection in fecal supernatants: in vivo proof that small bowel mucosa is the site of antiendomysial antibody production. Am J Gastroenterol 2002; 97:95–8.CrossrefGoogle Scholar

  • 10

    Malchow H, Ewe K, Brandes JV, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249–66.Google Scholar

  • 11

    Lockart-Mummery HE, Morson BC. Crohn’s disease of the large intestine and its distinction from ulcerative colitis. Gut 1960; 1:87–105.CrossrefGoogle Scholar

  • 12

    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index (CDAI). Gastroenterology 1979; 77:843–6.Google Scholar

  • 13

    Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87:971–6.Google Scholar

  • 14

    Walker-Smith JA, Guandalini S, Schmitz J, Shmerling DH, Visakorpi JK. Revisedcriteria for diagnosis of celiac disease. Arch Dis Child 1990; 65:909–11.Google Scholar

  • 15

    Vecchi M, Folli C, Donato MF, Formenti S, Arosio E, De Franchis R. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand J Gastroenterol 2003; 38:50–4.CrossrefGoogle Scholar

  • 16

    Peracchi M, Trovato C, Longhi M, Gasparin M, Conte D, Tarantino C, et al. Tissue transglutaminase antibodies in patients with end-stage heart failure. Am J Gastroenterol 2002; 97:2850–4.CrossrefGoogle Scholar

  • 17

    Picarelli A, Di Tola M, Sabbatella L, Vetrano S, Anania MC, Spadaro A, et al. Anti-tissue transglutaminase antibodies in arthritic patients: a disease-specific event? Clin Chem 2003; 49:2091–4.CrossrefGoogle Scholar

  • 18

    Carroccio A, Giannitrapani L, Soresi M, Not T, Iacono G, Di Rosa C, et al. Guinea pig transglutaminase immuno-linked assay does not predict celiac disease in patients with chronic liver disease. Gut 2001; 49:506–11.CrossrefGoogle Scholar

  • 19

    Marttinen A, Maki M. Purification of fibroblast-derived celiac disease auto-antigen molecules. Pediatr Res 1993; 34:420–3.CrossrefGoogle Scholar

  • 20

    Borner H, Osman AA, Meergans T, Weiske T, Mothes T. Isolation of antigens recognized by celiac disease auto-antibodies and their use in enzyme immunoassay of endomysium and reticulin antibody-positive human sera. Clin Exp Immunol 1996; 106:344–50.CrossrefGoogle Scholar

  • 21

    Lock J, Gilmour JEM, Unsworth DJ. Anti-tissue transglutaminase, anti-endomysium and anti-R1-reticulin auto-antibodies, the antibody trinity of coeliac disease. Clin Exp Immunol 1999; 116:258–62.CrossrefGoogle Scholar

  • 22

    Uhlig HH, Lichtenfeld J, Osman AA, Richter T, Mothes T. Evidence for existence of celiac disease autoantigens apart from tissue transglutaminase. Eur J Gastroenterol Hepatol 2000; 12:1017–20.CrossrefGoogle Scholar

  • 23

    Stulik J, Hernychova L, Porkertova S, Pozler O, Tuckova L, Sanchez D, et al. Identification of new celiac disease autoantigens using proteomic analysis. Proteomics 2003; 3:951–6.CrossrefGoogle Scholar

  • 24

    Korponay-Szabo IR, Laurila K, Szondy Z, Halttunen T, Szalai Z, Dahlbom I, et al. Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. Gut 2003; 52:199–204.Google Scholar

  • 25

    D’Argenio G, Biancone L, Cosenza V, Della Valle N, D’Armiento FP, Boirivant M, et al. Transglutaminases in Crohn’s disease. Gut 1995; 37:690–5.CrossrefGoogle Scholar

About the article

Received: 2004-05-24

Accepted: 2004-08-27

Published Online: 2005-06-01

Published in Print: 2004-10-01

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.225.

Export Citation

© Walter de Gruyter. Copyright Clearance Center

Comments (0)

Please log in or register to comment.
Log in